China Medipharm Insights - July 2000


Regular Price: USD 1,000.00

Special Price USD 700.00

30% OFF

* Required Fields

Regular Price: USD 1,000.00

Special Price USD 700.00


Be the first to review this product

Table of Contents

China Medipharm Insights - July 2000, China Medipharm InsightsDrug ConsumptionGeriatric Drug Consumption in Shanghai Ruijin Hospital in 1998-1999Product NewsViagra Cleared for Marketing in ChinaVioxx Enters Clinical Trials in ChinaNew Augmentin Launched by SmithKline & Beecham (Tianjin)Antifungal Lamisil Put Into ProductionGingko Extracts Obtain American PatentsWuhan Gingko Solution Cleared for Marketing in USNatural Vitamin E Enters MarketAntiviral Penciclovir MarketedAnti-tumor Arsenous Acid Injections DevelopedAntihypertensive Urapidil Cleared for MarketingAventis’ Essentiale to be Produced in China in 2001Ai Er Early Pregnancy Test Pen Cleared for MarketingCell Fusion Tumor Vaccine Completes Phase I Clinical TrialsLive Attenuated Chicken-Pox Vaccine DevelopedNew Recombinant Human Tumor Necrosis Factor-Nc Enters Phase II Clinical TrialAnti-Rheumatoid Interferon gama LaunchedTolmetin Put Into Production at Hangzhou MinshengNew HIV Detection & Confirmation Reagent Kit DevelopedP&G’s Calcium CCM Introduced Into China by Beijing AnkejieMarket AnalysisOverview of China Pharmaceutical Market in 1999 and Q1 2000Company ProfilesServier Tianjin Pharma to be Established999 Group Joins Hands With American CYTRANDaiichi (Beijing) Pharma Put Into ProductionLargest Amino Acid Producer Established in HubeiHarbin Group Reports 120 Increase in SalesLukang Records Fast Growth in Q1 2000North China Adjusts Product PortfolioQingdao Guofeng Group Co Ltd. EstablishedHangzhou Minsheng Pharma Group EstablishedShanghai Xin’an Gene Center EstablishedZhejiang Kangyu Pharma Produces Rimantadine and CefetametUbenimex Project of Kangyu Pharma Passes EvaluationBeijing Pharma Factory Merged Into Wanhui PharmaQianjiang Pharma Moving ForwardShanghai Saida Biopharma Sets Foot in Zhangjiang Hi-Tech ZoneBeijing Taiyang Makes Rapid ProgressShandong Luye Pharma Focuses on Natural Drug DevelopmentLarge Volume Parenterals Line in ShandongDNA Sequencing Co Established in WuhanTianjin Tianfa Pharma I&E Co. EstablishedJinling Pharma Booming on Mai Luo NingDiseases and ControlCancer Profiles in ChinaCervical; Endometrial & Ovarian Cancer Become the Three Major Gynecological CancersChina Proved to be High Risk Area for Alzheimer’s DiseaseTop 10 Causes of Death in XiamenAIDS & Venereal Disease Control Program Begins in UrumuqiSino-British Project on AIDS Control InitiatedChina Signs Agreement With Korea KOICA on Helminth ControlNews in BriefDemands for Drugs and Health Supplements Went Up in Q1 2000New Reimbursement Drug List ReleasedQuality of Chinese-Made Blood Products Competitive with Imported New Drug Customs Inspection Offices Set UpBeijing Reforms Free Healthcare SchemeHangzhou to Train Pharmacists for Drug Retailing Medical Expenditures Rise in BeijingBeijing Lowers Retail Drug Price AgainCommunity Healthcare Service in BeijingFujian Commences Rx and OTC Drug Classification SystemBasic Medical Insurance Scheme Launched in Xi’anBeijing Drug Valley Achieves Economy of Scale

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.